Regulatory NewsBREAK: Trump Administration Makes Most-Favored Nation Announcement

Topic(s):

Legislation & Regulation , Drug Pricing

On December 19, 2025, President Trump announced that nine more pharmaceutical manufacturers agreed to most favored nation drug pricing for Medicaid recipients in accordance with a May 12, 2025 Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients”.

The companies include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis, and Sanofi.

Each company announced price reductions for patients purchasing medications through the direct-to-consumer platform, TrumpRx.
Some companies announced donations of active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).
The companies committed to investing at least $150 billion collectively in U.S. manufacturing.

President Trump also expressed his belief that insurers should reduce their prices. The president said that he would invite insurance companies to work with him on reducing costs for Americans enrolled in health coverage.

More on This Topic:

For questions, please reach out to Vicky Jucelin.

Regulatory NewsBREAK February 24, 2026

Regulatory NewsBREAK: The FDA Releases Draft Framework to Accelerate Individualized Therapies for UltraRare Diseases

On February 23, 2026, the U.S. Food and Drug Administration (FDA) released draft guidance outlining a new regulatory framework to support approval of individualized therapies for ultra-rare diseases when randomized controlled trials are infeasible because of extremely small patient populations.

Legislation & Regulation, Rare Diseases

Regulatory NewsBREAK January 28, 2026

Regulatory NewsBREAK: CMS Announces List of Selected Drugs for IPAY 2028

On January 27, 2026, the Centers for Medicare and Medicaid Services (CMS) announced the list of drugs selected for the third round of the Medicare Drug Price Negotiation Program.

Legislation & Regulation

Regulatory NewsBREAK January 23, 2026

Regulatory NewsBREAK: OCR Rescinds Prior Civil Rights Guidance

On January 23, 2026, the U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) issued three notices: Rescission of Guidance to Nation’s Retail Pharmacies: Obligations under Federal Civil Rights Laws to Ensure Nondiscriminatory Access to Health Care at Pharmacies (Pharmacy Notice), Rescission of Guidance on Nondiscrimination Protections under the Church Amendments (Nondiscrimination Notice), and Rescission of Office for Civil Rights Documents under Executive Order 14192 (Additional Documents Notice).

Legislation & Regulation